GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of BCAB
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Big movements in BioAtla, Inc. stock price on Friday moving 19.29% between high and low
(Updated on Apr 19, 2024)

Sell candidate since Apr 15, 2024 Loss -26.40% PDF

The BioAtla, Inc. stock price fell by -13.37% on the last day (Friday, 19th Apr 2024) from $2.43 to $2.11. It has now fallen 6 days in a row. During the last trading day the stock fluctuated 19.29% from a day low at $2.10 to a day high of $2.51. The price has fallen in 8 of the last 10 days and is down by -44.61% for this period. Volume has increased on the last day by 437 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 794 thousand shares were bought and sold for approximately $1.67 million.

Given the current short-term trend, the stock is expected to rise 34.31% during the next 3 months and, with a 90% probability hold a price between $2.83 and $5.51 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

BCAB Signals & Forecast

There are few to no technical positive signals at the moment. The BioAtla, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.72 and $2.91. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, April 04, 2024, and so far it has fallen -46.30%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for BioAtla, Inc. stock

BioAtla, Inc. finds support from accumulated volume at $2.06 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.405 between high and low, or 19.29%. For the last week, the stock has had daily average volatility of 11.25%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (BCAB) For The Upcoming Trading Day Of Monday 22nd

For the upcoming trading day on Monday, 22nd we expect BioAtla, Inc. to open at $2.24, and during the day (based on 14 day Average True Range), to move between $1.81 and $2.40, which gives a possible trading interval of +/-$0.299 (+/-14.20%) up or down from last closing price. If BioAtla, Inc. takes out the full calculated possible swing range there will be an estimated 28.41% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $2.15 (2.14%) than the support at $2.06 (2.14%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is BioAtla, Inc. stock A Buy?

The BioAtla, Inc. stock holds several negative signals and despite the positive trend, we believe BioAtla, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -3.750 Sell Candidate Unchanged

Predicted Opening Price for BioAtla, Inc. of Monday, April 22, 2024

Fair opening price April 22, 2024 Current price
$2.24 ( 6.25%) $2.11

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for BCAB

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.64 25.49 %
R2 2.49 18.15 %
R1 2.39 13.60 %
Current price: 2.11
Support S1 2.08 -1.09 %
S2 1.99 -5.64 %
S3 1.83 -12.98 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.47 17.34 %
R2 2.41 14.49 %
R1 2.15 2.14 %
Current price 2.11
Support S1 2.06 -2.14%
S2 1.96 -6.89%
S3 1.88 -10.69%

FAQ

What is the symbol for BioAtla, Inc. Stock and on which exchange is it traded?
The symbol for BioAtla, Inc. is BCAB and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell BioAtla, Inc. Stock?
The BioAtla, Inc. stock holds several negative signals and despite the positive trend, we believe BioAtla, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy BioAtla, Inc. Stock?
BioAtla, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy BioAtla, Inc. Stock.

What's the current price of BioAtla, Inc. Stock?
As of the end of day on the 2024-04-19, the price of an BioAtla, Inc. (BCAB) share was $2.11.

What is the 52-week high and low for BioAtla, Inc. Stock?
The 52-week high for BioAtla, Inc. Stock is $4.07 and the 52-week low is $1.24.

What is the market capitalization of BioAtla, Inc. Stock?
As of the 2024-04-19, the market capitalization of BioAtla, Inc. is 121.685M.

When is the next earnings date for BioAtla, Inc.?
The upcoming earnings date for BioAtla, Inc. is May 09, 2024.
Click to get the best stock tips daily for free!

About BioAtla, Inc.

BioAtla. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, mel... BCAB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT